The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis

Metabolic dysfunction-associated steatotic liver disease (MASLD)—formerly known as non-alcoholic fatty liver disease (NAFLD)—is the most common chronic liver disease worldwide. Since there is currently no approved pharmacotherapy for MASLD, there is an urgent unmet need for efficacious therapeutics...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yvonne Burmeister, Kathrin Weyer, Achim Dörre, Bernd Seilheimer
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2023-12-01
Col·lecció:	Biomedicines
Matèries:	non-alcoholic fatty liver disease (NAFLD) non-alcoholic steatohepatitis (NASH) metabolic dysfunction-associated steatotic liver disease (MASLD) metabolic dysfunction-associated steatohepatitis (MASH) liver fibrosis
Accés en línia:	https://www.mdpi.com/2227-9059/11/12/3216
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!